Horizon Discovery Group plc Annual Report and Notice of Annual General Meeting (2832O)
16 May 2018 - 8:20PM
UK Regulatory
TIDMHZD
RNS Number : 2832O
Horizon Discovery Group plc
16 May 2018
This announcement replaces the earlier announcement (RNS:15620)
at 07:00, which stated the wrong date for the posting of the Annual
Report and Accounts and Notice of AGM to shareholders, now
corrected to 17 May 2018.
Horizon Discovery Group plc
("Horizon" or "the Company" or "the Group")
Annual Report and Notice of Annual General Meeting
Cambridge, UK, 16 May 2018: Horizon Discovery Group plc (LSE:
HZD), a global leader in gene editing and gene modulation
technologies, announces that its annual report and accounts for the
year ended 31 December 2017, which includes the notice convening
the Company's 2018 Annual General Meeting (AGM), will be posted to
shareholders tomorrow, Thursday 17(th) May 2018.
The annual report and accounts and notice of AGM will be
available on the Investor Relations section of the Company's
website at www.horizondiscovery.com.
The AGM will be held on Monday, 18 June 2018, and take place at
the Company's offices - Building 8100 Cambridge Research Park,
Waterbeach, Cambridge, CB25 9TL, commencing at 12.00 noon.
ENDS
For further information, please contact:
Horizon Discovery Group plc
Ian Gilham, Executive Chairman
Terry Pizzie, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
delivers inspired cell solutions using its translational genomics
platform, a highly precise and flexible suite of DNA editing (rAAV,
ZFN, CRISPR and Transposon) and modulation (RNAi, cDNA and ORF)
tools for research and clinical applications that advance human
health. Horizon's platforms and capabilities enable researchers to
alter almost any gene or modulate its function in human or
mammalian cell lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalized molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAESKFELPEFF
(END) Dow Jones Newswires
May 16, 2018 06:20 ET (10:20 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024
